Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | cyclin 6, putative | 0.0077 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0045 | 0.2782 | 0.2782 |
Echinococcus granulosus | cyclin dependent kinase 1 | 0.0045 | 0.2782 | 0.2782 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0045 | 0.2782 | 0.2782 |
Brugia malayi | Cyclin, N-terminal domain containing protein | 0.0077 | 1 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0045 | 0.2782 | 0.2782 |
Trypanosoma brucei | mitotic cyclin 6 | 0.0077 | 1 | 1 |
Echinococcus granulosus | 5'partial|cyclin dependent kinase 1 | 0.0045 | 0.2782 | 0.2782 |
Trichomonas vaginalis | cyclins, putative | 0.0077 | 1 | 1 |
Giardia lamblia | Kinase, CMGC CDK | 0.0045 | 0.2782 | 0.2782 |
Onchocerca volvulus | 0.0077 | 1 | 0.5 | |
Entamoeba histolytica | cell division protein kinase 2, putative | 0.0045 | 0.2782 | 0.2782 |
Echinococcus multilocularis | cyclin B | 0.0077 | 1 | 1 |
Leishmania major | cyclin | 0.0077 | 1 | 1 |
Trichomonas vaginalis | cyclin B, putative | 0.0077 | 1 | 1 |
Echinococcus multilocularis | cyclin dependent kinase 5 | 0.0045 | 0.2782 | 0.2782 |
Trichomonas vaginalis | cyclins, putative | 0.0077 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0045 | 0.2782 | 0.2782 |
Echinococcus multilocularis | cyclin dependent kinase | 0.0045 | 0.2782 | 0.2782 |
Loa Loa (eye worm) | CMGC/CDK/CDK5 protein kinase | 0.0045 | 0.2782 | 0.2782 |
Echinococcus multilocularis | cyclin dependent kinase 1 | 0.0045 | 0.2782 | 0.2782 |
Giardia lamblia | G2/mitotic-specific cyclin B | 0.0077 | 1 | 1 |
Brugia malayi | cell division control protein 2 homolog | 0.0045 | 0.2782 | 0.2782 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0045 | 0.2782 | 0.2782 |
Entamoeba histolytica | cell division protein kinase 2, putative | 0.0045 | 0.2782 | 0.2782 |
Echinococcus multilocularis | cyclin dependent kinase 1 | 0.0045 | 0.2782 | 0.2782 |
Plasmodium falciparum | protein kinase 5 | 0.0045 | 0.2782 | 1 |
Loa Loa (eye worm) | CMGC/CDK/CDC2 protein kinase | 0.0045 | 0.2782 | 0.2782 |
Schistosoma mansoni | cyclin B | 0.0077 | 1 | 1 |
Loa Loa (eye worm) | CMGC/CDK/CDC2 protein kinase | 0.0045 | 0.2782 | 0.2782 |
Trichomonas vaginalis | cyclin B, putative | 0.0077 | 1 | 1 |
Giardia lamblia | Kinase, CMGC CDK | 0.0045 | 0.2782 | 0.2782 |
Loa Loa (eye worm) | hypothetical protein | 0.0077 | 1 | 1 |
Trypanosoma cruzi | cyclin, putative | 0.0077 | 1 | 1 |
Trichomonas vaginalis | cyclin B, putative | 0.0077 | 1 | 1 |
Leishmania major | CYC2-like cyclin, putative,cyclin 6, putative | 0.0077 | 1 | 1 |
Trichomonas vaginalis | cyclin A, putative | 0.0077 | 1 | 1 |
Trypanosoma cruzi | CYC2-like cyclin, putative | 0.0077 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0045 | 0.2852 | 0.2852 |
Loa Loa (eye worm) | hypothetical protein | 0.0077 | 1 | 1 |
Echinococcus granulosus | cyclin dependent kinase | 0.0045 | 0.2782 | 0.2782 |
Trichomonas vaginalis | cyclins, putative | 0.0077 | 1 | 1 |
Echinococcus granulosus | cyclin B | 0.0077 | 1 | 1 |
Entamoeba histolytica | cyclin, putative | 0.0077 | 1 | 1 |
Trichomonas vaginalis | cyclins, putative | 0.0077 | 1 | 1 |
Trypanosoma cruzi | cyclin, putative | 0.0077 | 1 | 1 |
Toxoplasma gondii | cell-cycle-associated protein kinase CDK, putative | 0.0045 | 0.2782 | 0.5 |
Trichomonas vaginalis | cyclin B, putative | 0.0077 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0044 | 0.2676 | 0.2676 |
Brugia malayi | Protein kinase domain containing protein | 0.0045 | 0.2782 | 0.2782 |
Echinococcus granulosus | cyclin dependent kinase 5 | 0.0045 | 0.2782 | 0.2782 |
Trichomonas vaginalis | cyclins, putative | 0.0053 | 0.4577 | 0.4577 |
Plasmodium vivax | protein kinase Crk2 | 0.0045 | 0.2782 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.